Therefore, the identification of markers and tools to allow the modulation of individual ILC subsets in mice and humans, the development of standardized protocols, the deep characterization of melanoma-related ILCs and the identification of their key contribution to cancer development will be essential prior addressing the therapeutic modulation of ILCs. The gene discussed is CCL27; the disease is cancer.